The newly FDA-cleared Symbia Pro.specta SPECT/CT Scanner, which reportedly offers a variety of enhanced capabilities including low-dose CT up to 64 slices and intuitive workflow guides, was launched at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the Symbia Pro.specta™ SPECT/CT Scanner, according to Siemens Healthineers, the manufacturer of the device.
Launching the device at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, Siemens Healthineers said the single-photon emission computed tomography/computed tomography (SPECT/CT) system offers advanced imaging technology. Key benefits include automated SPECT motion correction and the ability to obtain up to 64 slices of low-dose CT to facilitate detailed image quality, according to the company.
In addition to optimal low-dose imaging, Siemens Healthineers noted the Symbia Pro.specta™ SPECT/CT Scanner offers myExam Companion, which provides automated workflow guidance. The company adds that clinicians will also have access to the device’s customized clinical tools designed to ensure optimal imaging with cardiology, neurology, oncology, and orthopedic applications.
Siemens Healthineers noted the Symbia Pro.specta™ SPECT/CT Scanner will offer improved accessibility, noting that it should fit in most existing SPECT rooms and is designed to replace the Symbia Intevo™ line of SPECT/CT scanners.
“Siemens Healthineers is proud to introduce the Symbia Pro.specta SPECT/CT scanner, which provides our customers with the ideal vehicle for transitioning from their SPECT-only and first-generation SPECT/CT cameras to a state-of-the-art SPECT/CT scanner that can perform a full spectrum of nuclear medicine examinations,” said Jim Williams, Ph.D., the head of Siemens Healthineers Molecular Imaging. “The Symbia Pro.specta will help health-care institutions overcome barriers to care by ensuring accessibility through its ease of use and ability to fit into existing SPECT rooms.”
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.